BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 6, 2017--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the appointment of George Migausky as interim Chief Financial
Officer. Mr. Migausky brings more than 30 years of experience in senior
financial management to Ocular Therapeutix. In his new role, he will
have Ocular’s financial and administrative groups reporting to him while
the Company continues to evaluate candidates for the permanent CFO role.
Mr. Migausky replaces Brad Smith who recently relinquished his role as
CFO at the Company.
“George is a highly regarded financial professional, offering extensive
expertise at high-growth private and public life sciences and
technology,” said Amar Sawhney, Ph.D., President, Chief Executive
Officer and Chairman of Ocular. “We believe his insights will be
invaluable as we continue to undertake pre-commercialization activities
for DEXTENZA™ in advance of the July 19th PDUFA date and as
we make further substantial progress across our additional drug product
development programs.”
Dr. Sawhney added, “On behalf of everyone at Ocular Therapeutix, I would
also like to thank Brad for his contributions at Ocular. He has been an
essential part of Ocular’s success and growth over the past three years,
and we wish him the best of luck in his future endeavors.”
Most recently, Mr. Migausky was Executive Vice President and Chief
Financial Officer of Dyax Corp., through its $6+ billion merger with
Shire plc in 2016. Previously, Mr. Migausky served as the CFO of
Wellstat Management Company, a firm responsible for strategy and
operations of an affiliated group of five life science companies. Prior
to this, he held CFO positions at several public and private companies,
including IGEN International, Inc., where he played a pivotal role in
the company’s IPO and subsequent $1.5 billion merger with F. Hoffman LaRoche. Mr. Migausky is on the Boards of Dimension Therapeutics, Inc. and
Hyperion Catalysis International, and is a trustee at the Massachusetts
Ear and Eye Infirmary. He received his M.B.A. degree from Babson College
and B.S. degree from Boston College.
“I am thrilled that Amar and his team have asked me to step into this
key role at Ocular,” said Mr. Migausky. “I look forward to working
closely with management and contributing to the Company’s advancement as
it plans for a potential product launch and commercialization.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4mg for intracanalicular use has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation occurring after ophthalmic surgery. The FDA has
accepted the Company’s NDA resubmission for DEXTENZA for the treatment
of ocular pain occurring after ophthalmic surgery and has established a
target PDUFA date of July 19, 2017. Ocular Therapeutix is also pursuing
additional indications for DEXTENZA. OTX-TP (travoprost insert) is in
Phase 3 clinical development for glaucoma and ocular hypertension.
Ocular Therapeutix is also evaluating injectable drug delivery depots
for back-of-the-eye diseases. Ocular Therapeutix's first product,
ReSure® Sealant, is FDA-approved to seal corneal incisions following
cataract surgery.
Forward-Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company including the development and regulatory
status of the Company’s product candidates, such as the Company’s
expectations and plans regarding regulatory submissions for and the
timing and conduct of clinical trials of DEXTENZA™ for post-surgical
ocular inflammation and pain, including our expectations regarding the
NDA filed with the FDA, DEXTENZA for the treatment of allergic
conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the
treatment of glaucoma and ocular hypertension, the potential utility of
any of the Company’s product candidates, potential commercialization of
the Company’s product candidates, the sufficiency of the Company’s cash
resources and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation and conduct of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some
point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170406005561/en/
Source: Ocular Therapeutix, Inc.
Investors
Burns McClellan on behalf of Ocular Therapeutix
Steve
Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Medical
Dynamics
Sandra Correa, 646-599-8637
Media and Business Group
Director
scorrea@rxmedyn.com
or
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Marketing
and Commercial Operations
scorning@ocutx.com
